BXRX · Baudax Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $30.0K | $14.0K | - | $238.0K | $300.0K | $422.0K | - | $281.0K | $201.0K |
| Cost of Revenue | $1.21M | $361.0K | $405.0K | - | $1.21M | $361.0K | $648.0K | - | $462.0K | $586.0K |
| Gross Profit | ($1.21M) | ($331.0K) | ($391.0K) | - | ($970.0K) | ($61.0K) | ($226.0K) | - | ($181.0K) | ($385.0K) |
| R&D | $1.90M | $1.78M | $2.92M | - | $645.0K | $912.0K | $1.29M | - | $658.0K | $857.0K |
| SG&A | $3.64M | $2.25M | $1.77M | - | $3.81M | $4.03M | $14.19M | - | $11.07M | $10.61M |
| Total Operating Expenses | $1.78M | $7.04M | $4.69M | - | $28.93M | $7.27M | $12.97M | - | $16.66M | $16.52M |
| D&A | $131.0K | $1.0K | $3.0K | - | $39.0K | $43.0K | $43.0K | - | $46.0K | $63.0K |
| Operating Income | ($1.78M) | ($7.04M) | ($4.69M) | - | ($28.70M) | ($6.97M) | ($12.54M) | - | ($16.38M) | ($16.32M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.93M) | ($7.38M) | $11.40M | - | ($29.20M) | ($7.53M) | ($12.81M) | - | ($16.96M) | ($15.33M) |
| EPS - Basic | ($0.30) | ($1.51) | ($126.87) | - | ($2.47) | ($1.05) | - | - | ($0.20) | ($0.20) |
| EPS - Diluted | ($0.30) | ($1.51) | ($126.87) | - | ($2.47) | ($1.05) | - | - | ($0.20) | ($1.72) |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $363.0K | $1.42M | $3.80M | $5.26M | $5.65M | $5.21M | $11.53M | $15.89M | $14.77M | $25.41M |
| Accounts Receivable | - | - | - | $335.0K | $313.0K | $616.0K | $608.0K | $542.0K | $422.0K | $219.0K |
| Inventory | - | - | - | $0 | $4.48M | $5.25M | $5.21M | $5.00M | $4.31M | $3.56M |
| Accounts Payable | $7.82M | $5.83M | $3.84M | $3.93M | $3.61M | $3.06M | $3.28M | $1.47M | $1.82M | $2.08M |
| Current Assets | $1.34M | $1.86M | $4.11M | $6.35M | $11.27M | $12.48M | $19.72M | $23.49M | $31.14M | $43.28M |
| Total Assets | $20.58M | $21.32M | $7.07M | $10.03M | $17.51M | $40.83M | $48.81M | $53.28M | $61.50M | $73.81M |
| Current Liabilities | $19.05M | $20.46M | $12.37M | $21.46M | $21.27M | $18.18M | $20.40M | $15.65M | $14.44M | $13.82M |
| Long-term Debt | $0 | $0 | $1.43M | $1.52M | $2.17M | $5.10M | $5.71M | $6.31M | $6.91M | $7.52M |
| Total Liabilities | $21.78M | $22.95M | $14.38M | $34.27M | $37.05M | $36.60M | $39.07M | $40.05M | $82.23M | $78.38M |
| Stockholders' Equity | ($10.24M) | ($10.68M) | ($7.31M) | ($24.24M) | ($19.54M) | $4.23M | $9.74M | $13.23M | ($20.73M) | ($4.57M) |
| Retained Earnings | ($189.30M) | ($186.88M) | ($179.50M) | ($190.90M) | ($181.65M) | ($152.43M) | ($144.90M) | ($132.09M) | ($161.52M) | ($144.56M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.94M) | - | - | - | ($12.90M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | ($20.0K) | - | - | - |
| Financing Cash Flow | - | - | $3.21M | - | - | - | $8.56M | - | - | - |
| CapEx | - | - | - | - | - | - | $20.0K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($12.92M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | -1103.3% | -2792.9% | - | -407.6% | -20.3% | -53.6% | - | -64.4% | -191.5% |
| Operating margin | - | -23483.3% | -33485.7% | - | -12057.1% | -2324.0% | -2972.7% | - | -5829.2% | -8117.4% |
| EBITDA margin | - | -23480.0% | -33464.3% | - | -12040.8% | -2309.7% | -2962.6% | - | -5812.8% | -8086.1% |
| Net margin | - | -24583.3% | 81457.1% | - | -12271.0% | -2510.3% | -3035.3% | - | -6036.3% | -7626.4% |
| Free cash flow margin | - | - | - | - | - | - | -3062.3% | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 1.01 | - | - | - |
| R&D / Revenue | - | 5930.0% | 20835.7% | - | 271.0% | 304.0% | 306.4% | - | 234.2% | 426.4% |
| SG&A / Revenue | - | 7513.3% | 12650.0% | - | 1600.0% | 1343.0% | 3362.6% | - | 3940.9% | 5277.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.4% | -34.6% | 161.4% | - | -166.8% | -18.4% | -26.2% | - | -27.6% | -20.8% |
| Return on equity | 18.9% | 69.1% | -155.9% | - | 149.5% | -178.0% | -131.5% | - | 81.8% | 335.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.07 | 0.09 | 0.33 | 0.30 | 0.53 | 0.69 | 0.97 | 1.50 | 2.16 | 3.13 |
| Quick ratio | 0.07 | 0.09 | 0.33 | 0.30 | 0.32 | 0.40 | 0.71 | 1.18 | 1.86 | 2.87 |
| Cash ratio | 0.02 | 0.07 | 0.31 | 0.25 | 0.27 | 0.29 | 0.57 | 1.02 | 1.02 | 1.84 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | -0.20 | -0.06 | -0.11 | 1.21 | 0.59 | 0.48 | -0.33 | -1.64 |
| Debt / Assets | 0.00 | 0.00 | 0.20 | 0.15 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -2.01 | -2.00 | -0.97 | -0.41 | -0.90 | 9.65 | 5.01 | 4.03 | -2.97 | -16.14 |
| Liabilities / Assets | 1.06 | 1.08 | 2.04 | 3.42 | 2.12 | 0.90 | 0.80 | 0.75 | 1.34 | 1.06 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.01 | 0.01 | 0.01 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | 0.27 | 0.07 | 0.12 | - | 0.11 | 0.16 |
| Days sales outstanding | - | - | - | - | 480d | 749d | 526d | - | 548d | 398d |
| Days inventory outstanding | - | - | - | - | 1353d | 5313d | 2936d | - | 3405d | 2216d |
| Days payable outstanding | 2363d | 5893d | 3458d | - | 1090d | 3098d | 1850d | - | 1437d | 1299d |
| Cash conversion cycle | - | - | - | - | 742d | 2965d | 1612d | - | 2516d | 1315d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | -90.0% | -96.7% | - | -15.3% | 49.3% | 113.1% | - | 313.2% | -42.4% |
| Revenue CAGR (3y) | - | -55.9% | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -24.5% | -442.6% | -73.0% | - | -435.9% | 84.2% | 63.7% | - | 61.7% | -27.9% |
| Operating income growth (YoY) | 93.8% | -1.0% | 62.6% | - | -75.2% | 57.3% | 23.1% | - | - | -54.4% |
| Net income growth (YoY) | 93.4% | 2.1% | - | - | -72.2% | 50.9% | 24.3% | - | - | 49.7% |
| EPS growth (YoY) | 87.9% | -43.8% | - | - | -1135.0% | 39.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | 8.2% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 47.6% | - | - | - | 5.7% | - | - | - | 54.2% | 92.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Baudax Bio against the 5 most active filers in the same SIC group.